Publication Products
| Chemical Structure | Cat. No. | Product Name | CAS No. |
|---|
 |
BCP28287 | CB-839 | 1439399-58-2 |
CB-839 is a potent and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC), and with IC50s of 23 nM and 28 nM in kidney and brain, respectively.
|
|||
 |
BCP01841 | Mirdametinib New | 391210-10-9 |
Mirdametinib, also known as PD-0325901, is a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity.
|
|||
 |
BCP02037 | Ponatinib New | 943319-70-8 |
Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.
|
|||
 |
BCP01714 | GDC-0941 New | 957054-30-7 |
Pictilisib, also known as Pictrelisib, GDC-0941, RG7321 and GNE0941 , is an orally bioavailable, and is a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity.
|
|||
 |
BCP01984 | Orantinib New | 252916-29-3 |
TSU-68 (SU6668)is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively.
|
|||
 |
BCP01874 | Lapatinib New | 231277-92-2 |
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
|
|||
 |
BCP02857 | Camptothecin New | 7689-03-4 |
Camptothecin is a potent DNA enzyme topoisomerase I inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231.
|
|||
 |
BCP00195 | LY294002 New | 154447-36-6 |
LY294002 is a highly selective inhibitor of phosphatidylinositol 3-kinase.
|
|||
 |
BCP01404 | Rapamycin New | 53123-88-9 |
Rapamycin is antifungal and immunosuppressant and specific inhibitor of mTOR.
|
|||
 |
BCP27641 | Cabazitaxel Hot | 183133-96-2 |
A novel semi-synthetic taxane with antitumor activity used for the treatment of castration-resistant prostate cancer. A microtubule inhibitor.
|
|||
 |
BCP02337 | Plerixafor New | 110078-46-1 |
Plerixafor (AMD3100) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.
|
|||
 |
BCP06962 | Empagliflozin New | 864070-44-0 |
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes.
|
|||
 |
BCP32728 | CL2A-SN-38 New | 1279680-68-0 |
CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).
|
|||
 |
BCP28882 | Cintirorgon New | 2055536-64-4 |
Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (RORγ) agonist.
|
|||
 |
BCP01925 | Vandetanib New | 443913-73-3 |
Vandetanib is a multi-kinase inhibitor that is used in the therapy of advanced or metastatic medullary thyroid cancer. Vandetanib therapy is commonly associated with transient elevations in serum aminotransferase during therapy, but has not been linked to cases of clinically apparent acute liver injury with jaundice.
|
|||
 |
BCP01725 | ABT-737 | 852808-04-9 |
ABT-737 is a pan-Bcl-2 inhibitor that has a wide range of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts.
|
|||
 |
BCP05458 | U0126-EtOH New | 1173097-76-1 |
U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. This inhibition of MEK1/2 is noncompetitive with ERK and ATP.
|
|||
 |
BCP04467 | Afatinib | 850140-72-6 |
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.
|
|||
 |
BCP02171 | AZD8055 | 1009298-09-2 |
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
|
|||
 |
BCP06035 | Sofosbuvir | 1190307-88-0 |
PSI-7977 is an investigational nucleotide analog currently in Phase 2 for treatment of chronic HCV infection.
|
|||
